glucose, (beta-d)-isomer has been researched along with Overweight in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 5 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bodicoat, DH; Chatterjee, S; Davies, MJ; Edwardson, CL; Gray, LJ; Khunti, K; King, JA; Poulin, B; Redman, EL; Sargeant, JA; Stensel, DJ; Waheed, G; Waller, HL; Webb, DR; Wilding, JPH; Willis, SA; Yates, T | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Dejgaard, TF; Færch, K; Jørgensen, ME; Karstoft, K; Pedersen, C; Persson, F; Ried-Larsen, M; Tvermosegaard, M; Vainø, CTR; Vistisen, D | 1 |
| Dashora, U; Dhatariya, K; Gregory, R; Macklin, A; Nagi, D; Patel, DC; Rayman, G; Rowles, S; Winocour, P | 1 |
| Elkind-Hirsch, KE; Harris, R; Seidemann, E | 1 |
| Bhatt, DL; Cahn, A; Diaz, R; Gause-Nilsson, IAM; Goudev, A; Kuder, J; Leiter, LA; McGuire, DK; Mosenzon, O; Murphy, SA; Oyama, K; Park, KS; Raz, I; Sabatine, MS; Špinar, J; Wilding, JPH; Wiviott, SD | 1 |
| Aoki, C; Aso, Y; Kato, K; Niitani, T; Sagara, M; Suzuki, K; Wakamatsu, S; Yanagi, K | 1 |
| de J Patiño-Laguna, A; Díaz-Cruz, C; González-Ortiz, M; Grover-Páez, F; López-Murillo, LD; Martínez-Abundis, E | 1 |
| Matsuba, I; Matsuba, R; Nagai, Y; Shimokawa, M; Tanaka, Y | 1 |
| Ghosh, A; Heise, T; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S | 1 |
| Bays, HE; Canovatchel, W; Law, G; Weinstein, R | 1 |
| Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R | 1 |
| Broedl, UC; Christiansen, AV; Häring, HU; Kim, G; Meinicke, T; Merker, L; Roux, F; Salsali, A; Woerle, HJ | 1 |
| Adkins, YC; Bonnel, EL; Breksa, AP; Freytag, TL; Kelley, DS; Mackey, BE; Manners, GD; Storms, DH; Woodhouse, LR; Zunino, SJ | 1 |
| Dobbins, RL; Hussey, EK; Kapur, A; Layko, D; Murray, SC; Nunez, DJ; O'Connor-Semmes, RL; Stockman, NL; Stoltz, RR | 1 |
13 trial(s) available for glucose, (beta-d)-isomer and Overweight
| Article | Year |
|---|---|
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Appetite; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Ghrelin; Glucagon-Like Peptide 1; Glucose; Glucosides; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Overweight; Peptide YY; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2022 |
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Denmark; Exercise; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Overweight; Prediabetic State; Treatment Outcome | 2021 |
A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucosides; Humans; Hypoglycemic Agents; Metformin; Overweight; Pregnancy; Prospective Studies; Single-Blind Method | 2020 |
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Obesity; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Composition; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
Dapagliflozin administration on visceral adiposity, blood pressure and aortic central pressure in overweight patients without type 2 diabetes.
Topics: Adipose Tissue; Arterial Pressure; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Male; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Viscera | 2017 |
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance.
Topics: Adiposity; Anti-Obesity Agents; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Electric Impedance; Glucose Clamp Technique; Glucosides; Glycated Hemoglobin; Hyperglycemia; Hypoglycemia; Insulin Resistance; Overweight; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2018 |
Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
Topics: Blood Glucose; Body Mass Index; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycosuria; Humans; Hyperglycemia; Hypoglycemic Agents; Kidney; Kidney Function Tests; Male; Membrane Transport Modulators; Middle Aged; Overweight; Postprandial Period; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.
Topics: Adult; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Body Weight; Canagliflozin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose; Glucosides; Humans; Male; Middle Aged; Obesity; Overweight; Sodium-Glucose Transport Proteins; Thiophenes; Treatment Outcome | 2014 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Female; Glucosides; Health Care Costs; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Overweight; Quality-Adjusted Life Years; Risk; Sodium-Glucose Transport Proteins; Sulfonylurea Compounds; United Kingdom; Weight Loss | 2015 |
Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Exercise; Female; Glucosides; Humans; Hyperglycemia; Hypertension; Hypoglycemia; Hypoglycemic Agents; Male; Membrane Transport Modulators; Metformin; Middle Aged; Overweight; Sodium-Glucose Transporter 2 Inhibitors | 2015 |
Dietary supplementation with purified citrus limonin glucoside does not alter ex vivo functions of circulating T lymphocytes or monocytes in overweight/obese human adults.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Beverages; Biomarkers; Body Mass Index; Cell Proliferation; Cells, Cultured; Citrus; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Female; Fruit; Glucosides; Hepatitis; Humans; Limonins; Male; Metabolic Syndrome; Middle Aged; Monocytes; Obesity; Overweight; T-Lymphocytes | 2016 |
Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Female; Glucosides; Glycosuria; Half-Life; Humans; Insulin; Male; Middle Aged; Obesity; Overweight; Prodrugs; Water-Electrolyte Balance | 2010 |
1 other study(ies) available for glucose, (beta-d)-isomer and Overweight
| Article | Year |
|---|---|
Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemic Agents; Insulin; Overweight; Practice Guidelines as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Kingdom | 2021 |